Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Juliana Di Iulio"'
Autor:
Louise Kostos, James P. Buteau, Theresa Yeung, Juliana Di Iulio, Jing Xie, Anthony Cardin, Kwang Y. Chin, Brittany Emmerson, Katie L. Owen, Belinda S. Parker, Heidi Fettke, Luc Furic, Arun A. Azad, Michael S. Hofman
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Background[177Lu]Lu-PSMA is a radioligand therapy used in metastatic castration-resistant prostate cancer (mCRPC). Despite a survival benefit, the responses for many patients receiving [177Lu]Lu-PSMA are not durable, and all patients eventually devel
Externí odkaz:
https://doaj.org/article/ee75493d95874a12b67e6d0f0cb88f42
Autor:
Harry Iland, Ken Bradstock, John Seymour, Mark Hertzberg, Andrew Grigg, Kerry Taylor, John Catalano, Paul Cannell, Noemi Horvath, Sandra Deveridge, Peter Browett, Tim Brighton, Li Chong, Francisca Springall, Juliet Ayling, Alberto Catalano, Shane Supple, Marnie Collins, Juliana Di Iulio, John Reynolds
Publikováno v:
Haematologica, Vol 97, Iss 2 (2012)
Background Initial therapy for patients with acute promyelocytic leukemia most often involves the combination of all-trans-retinoic acid with anthracycline-based chemotherapy. The role of non-anthracycline drugs in induction and consolidation is less
Externí odkaz:
https://doaj.org/article/740f6d736e0d4fe0ace5749b6c255562
Autor:
Ian G. Campbell, Kelly Anne Phillips, Judy Kirk, Geoffrey J. Lindeman, Juliana Di Iulio, Alvin Milner, Lisa Devereux, Sandra A. Johnson, Gillian Mitchell, Yoland C. Antill
Supplementary Table 1 from Gene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f956c3cb34d5b1c4d5587a8df1d4aa9
https://doi.org/10.1158/1055-9965.22437916.v1
https://doi.org/10.1158/1055-9965.22437916.v1
Autor:
Ian G. Campbell, Kelly Anne Phillips, Judy Kirk, Geoffrey J. Lindeman, Juliana Di Iulio, Alvin Milner, Lisa Devereux, Sandra A. Johnson, Gillian Mitchell, Yoland C. Antill
Purpose: Genomic alterations (including gene hypermethylation) are likely to precede the phenotypic changes associated with breast tumorigenesis. From a prospective collection of ductal lavage (DL) samples from women with a known mutation in BRCA1 or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34cad5561e9f08d563f326c3eb7a8c68
https://doi.org/10.1158/1055-9965.c.6516118.v1
https://doi.org/10.1158/1055-9965.c.6516118.v1
Autor:
Louise Kathleen Kostos, James Patrick Buteau, Grace Kong, Theresa Yeung, Juliana Di Iulio, Michael T Fahey, Heidi Fettke, Luc Furic, Michael S Hofman, Arun Azad
Publikováno v:
Journal of Clinical Oncology. 41:TPS278-TPS278
TPS278 Background: [177Lu]Lu-PSMA-617 was recently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Despite conferring a survival benefit, for many the treatment response is short, and progression is inevitable. O
Autor:
Louise Kathleen Kostos, James Patrick Buteau, Theresa Yeung, Sophia Xie, Juliana Di Iulio, Anthony Cardin, Katie Owen, Heidi Fettke, Kwang Y Chin, Brittany Emmerson, Mohammad B Haskali, Belinda Parker, Luc Furic, Arun Azad, Michael S Hofman
Publikováno v:
Journal of Clinical Oncology. 41:TPS280-TPS280
TPS280 Background: [177Lu]Lu-PSMA-I&T (LuPSMA) is a small molecule radioligand that delivers radiation via beta-particulate emission to cells expressing prostate-specific membrane antigen (PSMA). Despite a survival benefit in mCRPC, responses for man
Autor:
David Westerman, Mary Ann Anderson, Mathias Bressel, Mark A. Dawson, Martin Dreyling, Sasanka M. Handunnetti, Juliana Di Iulio, Sarah-Jane Dawson, Rodney J. Hicks, Rishu Agarwal, Christiane Pott, Constantine S. Tam, Kate Burbury, Andrew W. Roberts, Stephen Lade, John F. Seymour, Gillian M. Turner
Publikováno v:
New England Journal of Medicine. 378:1211-1223
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma. Complete response rates of 21% have been observed for each agent when administered as long-term continuous therapy.
Autor:
Juliana Di Iulio, Paul Cannell, Andrew W. Roberts, Anthony K. Mills, Warwick J. Benson, Andrew H. Wei, James D'Rozario, John Moore, Mark P. Hertzberg, Emma Link, Ray M. Lowenthal, Michael F. Leahy, Luke Coyle, Campbell Tiley, John Taper, Phillip Campbell, Lynda J. Campbell, Ian D. Lewis, Ilona Cunningham, A Enno, Philip A. Rowlings, Peter G Bardy, Jeff Szer, Paula Marlton, Andrew Grigg, Anthony P. Schwarer, Uwe Hahn, Kenneth F. Bradstock, Kimberly Cartwright, Devinder Gill, John F. Seymour, Gavin Cull, Sandra Deveridge
Publikováno v:
Journal of Clinical Oncology. 35:1678-1685
Purpose Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown to improve remission rates and survival. We hypothesized that improvements in outcomes in adult AML may be further achiev
Autor:
John F. Seymour, Sasanka M. Handunnetti, Kate Burbury, Andrew W. Roberts, Stephen Lade, David Westerman, Amit Khot, Juliana Di Iulio, Mary Ann Anderson, Constantine S. Tam, Rodney J. Hicks, Besiat Birbirsa, Piers Blombery, David Ritchie, Mathias Bressel
Publikováno v:
Blood. 134:3999-3999
Background: Marginal zone lymphoma (MZL) is an incurable but heterogeneous disorder for which there is no standard of care treatment in the relapsed/refractory (R/R) setting. The BTK inhibitor, ibrutinib (IB) is well tolerated with an overall respons
Autor:
Sarah-Jane Dawson, Constantine S. Tam, Rishu Agarwal, Rodney J. Hicks, Mary Ann Anderson, Mark A. Dawson, Mathias Bressel, David Westerman, David Ritchie, Sasanka M. Handunnetti, Kate Burbury, Andrew W. Roberts, Rachel Koldej, Stephen Lade, John F. Seymour, Juliana Di Iulio, Besiat Birbirsa
Publikováno v:
Blood. 134:756-756
Background: The phase II AIM trial (Tam et al, NEJM 2018; NCT02471391), using combination BTK inhibitor ibrutinib (IB) and BCL-2 inhibitor venetoclax (VEN) therapy achieved excellent 16 week complete remission rates (CRR) (primary endpoint; 62%) in p